Huntington's disease, formerly known as "St. Vitus' dance," is a rare and incurable brain disorder characterized by movement disorders. Those affected often remain unaware of their condition for a ...

SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study of INGREZZA® (valbenazine) capsules ...

Huntington's chorea (also known as St. Vitus' dance) is a rare brain disorder that causes, among other symptoms, uncontrollable, jerky movements in individuals. Photo: Getty Images/Science Photo ...

A new drug was approved for Huntington's chorea in 2023, and novel insights about Huntington's disease emerged in new research. Valbenazine for Huntington's Chorea In August, the FDA expanded the ...

SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults with ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an established long-term safety profile, tolerability and sustained ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) announced on Monday that new data on INGREZZA or valbenazine capsules showed consistently greater improvements in HD chorea associated with Huntington's ...

Robust and sustained improvements in chorea associated with Huntington's disease were observed through Week 104 in patients, irrespective of concomitant antipsychotic therapy use. These results ...

Those affected often remain unaware of their condition for a long time—to outsiders, it may seem as if the person is gesticulating in an exaggerated manner. Over time, the cognitive abilities of those ...

SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® (valbenazine) capsules ...